Soterix Medical Inc. (SMI) was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. Founded in 2008, SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 350 medical centers in the US and worldwide. SMI has licensed and developed a comprehensive intellectual property portfolio that includes High-Definition transcranial Direct Current Stimulation (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. Ongoing Phase I, II, IIb, and III trials use investigational devices that are regulated/limited by US or Federal law. SMI is proudly based in New York City with international distributors in all major markets.
At Soterix Medical, Engineering Serving Humanity means that we are committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.
237 W 35 ST,NEW YORK, NY 10001
ISO 13485:2012 certifiedMDSAP certifiedFDA Registered Facility
Each channel can deliver either positive or negative Direct Current (tDCS) while the common reference channel balances the residual current to ensure current conservation.
Each channel can deliver either positive or negative Alternating Current (tACS), Pulse Current (tPCS), Random Noise (tRNS), Oscillating Direct Current (tODCS) in addition to Direct Current (tDCS) while the common reference channel balances the residual current to ensure current conservation.